ImmunoSpot® stands for >25 years of leadership in immune monitoring by ELISPOT/FluoroSpot

CTL's founder and CEO, Prof. Dr. Paul V. Lehmann

Reliable detection of rare antigen-specific T and/or B cells has been a major challenge for immune monitoring. For over two decades, CTL has been leading this field with its ImmunoSpot® platform. View a lecture in which Prof. Dr. Paul V. Lehmann (see CV), CTL's Founder and CEO, explains how.

Prof. Lehmann and scientists working with him were the FIRST to:
More of CTL/Prof. Lehmann’s publications on ELISPOT are sorted here by theme, providing more information on the basics of ELISPOT and how it can be put to innovative use, possibly offering useful references for you.
If you have any questions about immune monitoring by ELISPOT/FluoroSpot, contact us, as we take pride in sharing our expertise with you.